Wikidata

(Q63815615)

English

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

clinical trial

In more languages

Statements

title
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis (English)
0 references
medical condition
sclerosis
0 references
multiple sclerosis
0 references
sponsor
Hoffmann-La Roche
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Bulgaria
0 references
Chile
0 references
Estonia
0 references
Finland
0 references
France
0 references
Germany
0 references
Hungary
0 references
Israel
0 references
Italy
0 references
Latvia
0 references
Lithuania
0 references
Mexico
0 references
Netherlands
0 references
New Zealand
0 references
Peru
0 references
Poland
0 references
Portugal
0 references
Serbia
0 references
Slovakia
0 references
South Africa
0 references
Spain
0 references
Switzerland
0 references
Tunisia
0 references
Ukraine
0 references
United Kingdom
0 references
start time
31 August 2011
0 references
end time
2 April 2015
0 references
number of participants
821
0 references
minimum age
18 year
0 references
maximum age
55 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63815615&oldid=1857399106"